<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35808102</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-4991</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Nanomaterials (Basel, Switzerland)</Title><ISOAbbreviation>Nanomaterials (Basel)</ISOAbbreviation></Journal><ArticleTitle>Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nano12132267</ELocationID><Abstract><AbstractText>Enabling challenging applications of nanomedicine and precision medicine in the treatment of neurodegenerative disorders requires deeper investigations of nanocarrier-mediated biomolecular delivery for neuronal targeting and recovery. The successful use of macromolecular biotherapeutics (recombinant growth factors, antibodies, enzymes, synthetic peptides, cell-penetrating peptide-drug conjugates, and RNAi sequences) in clinical developments for neuronal regeneration should benefit from the recent strategies for enhancement of their bioavailability. We highlight the advances in the development of nanoscale materials for drug delivery in neurodegenerative disorders. The emphasis is placed on nanoformulations for the delivery of brain-derived neurotrophic factor (BDNF) using different types of lipidic nanocarriers (liposomes, liquid crystalline or solid lipid nanoparticles) and polymer-based scaffolds, nanofibers and hydrogels. Self-assembled soft-matter nanoscale materials show favorable neuroprotective characteristics, safety, and efficacy profiles in drug delivery to the central and peripheral nervous systems. The advances summarized here indicate that neuroprotective biomolecule-loaded nanoparticles and injectable hydrogels can improve neuronal survival and reduce tissue injury. Certain recently reported neuronal dysfunctions in long-COVID-19 survivors represent early manifestations of neurodegenerative pathologies. Therefore, BDNF delivery systems may also help in prospective studies on recovery from long-term COVID-19 neurological complications and be considered as promising systems for personalized treatment of neuronal dysfunctions and prevention or retarding of neurodegenerative disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CNRS, Institut Galien Paris-Saclay, Universit&#xe9; Paris-Saclay, F-92290 Ch&#xe2;tenay-Malabry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rakotoarisoa</LastName><ForeName>Miora</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CNRS, Institut Galien Paris-Saclay, Universit&#xe9; Paris-Saclay, F-92290 Ch&#xe2;tenay-Malabry, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelov</LastName><ForeName>Borislav</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Na Slovance 2, CZ-18221 Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yuru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Wenzhou Institute, University of Chinese Academy of Sciences, No. 1, Jinlian Road, Longwan District, Wenzhou 325001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelova</LastName><ForeName>Angelina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0285-0637</Identifier><AffiliationInfo><Affiliation>CNRS, Institut Galien Paris-Saclay, Universit&#xe9; Paris-Saclay, F-92290 Ch&#xe2;tenay-Malabry, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CZ.02.1.01/0.0/0.0/15_003/0000447 "Structural Dynamics of Biomolecular Systems" (ELIBIO)</GrantID><Agency>European Regional Development Fund</Agency><Country/></Grant><Grant><GrantID>CZ.02.1.01/0.0/0.0/16_019/0000789 "Advanced research using high-intensity laser produced photons and particles"</GrantID><Agency>European Regional Development Fund</Agency><Country/></Grant><Grant><GrantID>3+3 program, No. 204, item 27 from 25.03.2020</GrantID><Agency>JINR, Dubna</Agency><Country/></Grant><Grant><GrantID>WIUCASQD2019005</GrantID><Agency>Wenzhou Institute, University of Chinese Academy of Sciences</Agency><Country/></Grant><Grant><GrantID>31670841</GrantID><Agency>National Natural Science Foundation China</Agency><Country/></Grant><Grant><GrantID>ANR-11-IDEX-0003-02 &amp;quot;IDI 2017&amp;quot; IDEX Paris-Saclay</GrantID><Agency>Agence Nationale de la Recherche France</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nanomaterials (Basel)</MedlineTA><NlmUniqueID>101610216</NlmUniqueID><ISSNLinking>2079-4991</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biotherapeutics</Keyword><Keyword MajorTopicYN="N">brain-derived neurotrophic factor (BDNF)</Keyword><Keyword MajorTopicYN="N">lipid nanoparticles</Keyword><Keyword MajorTopicYN="N">nanocarriers</Keyword><Keyword MajorTopicYN="N">nanofibers</Keyword><Keyword MajorTopicYN="N">nanomedicine for growth factor delivery</Keyword><Keyword MajorTopicYN="N">neuroprotective assemblies</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the bibliography; in the writing of the manuscript; or in the decision to publish the work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35808102</ArticleId><ArticleId IdType="pmc">PMC9268293</ArticleId><ArticleId IdType="doi">10.3390/nano12132267</ArticleId><ArticleId IdType="pii">nano12132267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Karlawish J., Jack C.R., Jr., Rocca W.A., Snyder H.M., Carrillo M.C. Alzheimer&#x2019;s Disease: The next frontier&#x2014;Special report. Alzheimer Dement. 2017;13:374&#x2013;380. doi: 10.1016/j.jalz.2017.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.02.006</ArticleId><ArticleId IdType="pubmed">28314660</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association 2016 Alzheimer&#x2019;s disease facts and figures. Alzheimer Dement. 2016;12:459&#x2013;509. doi: 10.1016/j.jalz.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.03.001</ArticleId><ArticleId IdType="pubmed">27570871</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., Blennow K., Breteler M.M., de Strooper B., Frisoni G.B., Salloway S., Van der Flier W.M. Alzheimer&#x2019;s disease. Lancet. 2016;388:505&#x2013;517. doi: 10.1016/S0140-6736(15)01124-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)01124-1</ArticleId><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Aarsland D., Creese B., Politis M., Chaudhuri K.R., Ffytche D.H., Weiutraub D., Ballard C. Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 2017;13:217&#x2013;231. doi: 10.1038/nrneurol.2017.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.27</ArticleId><ArticleId IdType="pmc">PMC5643027</ArticleId><ArticleId IdType="pubmed">28257128</ArticleId></ArticleIdList></Reference><Reference><Citation>Titova N., Padmakumar C., Lewis S.J.G., Chaudhuri K.R. Parkinson&#x2019;s: A syndrome rather than a disease? J. Neural Transm. 2017;124:907&#x2013;914. doi: 10.1007/s00702-016-1667-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-016-1667-6</ArticleId><ArticleId IdType="pmc">PMC5514217</ArticleId><ArticleId IdType="pubmed">28028643</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestrino R., Schapira A.H.V. Parkinson disease. Eur. J. Neurol. 2020;27:27&#x2013;42. doi: 10.1111/ene.14108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14108</ArticleId><ArticleId IdType="pubmed">31631455</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha N.K., Ojha S., Jha S.K., Dureja H., Singh S.K., Shukla S.D., Chellappan D.K., Gupta G., Bhardwaj S., Kumar N., et al. Evidence of coronavirus (CoV) pathogenesis and emerging pathogen SARS-CoV-2 in the nervous system: A review on neurological impairments and manifestations. J. Mol. Neurosci. 2021;71:2192&#x2013;2209. doi: 10.1007/s12031-020-01767-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-020-01767-6</ArticleId><ArticleId IdType="pmc">PMC7814864</ArticleId><ArticleId IdType="pubmed">33464535</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.M., Tan B.H., Wu S., Gui Y., Suo J.L., Li Y.C. Evidence of central nervous system infection and neuroinvasive routes, as well as neurological involvement, in the lethality of SARS-CoV-2 infection. J. Med. Virol. 2020;93:1304&#x2013;1313. doi: 10.1002/jmv.26570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26570</ArticleId><ArticleId IdType="pmc">PMC7537172</ArticleId><ArticleId IdType="pubmed">33002209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancheva L., Petralia M.C., Miteva S., Dragomanova S., Solak A., Kalfin R., Lazarova M., Yarkov D., Ciurleo R., Cavalli E., et al. Emerging neurological and psychobiological aspects of COVID-19 infection. Brain Sci. 2020;10:852. doi: 10.3390/brainsci10110852.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10110852</ArticleId><ArticleId IdType="pmc">PMC7696269</ArticleId><ArticleId IdType="pubmed">33198412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuzzo D., Cambula G., Bacile I., Rizzo M., Galia M., Mangiapane P., Scalisi L. Long-term brain disorders in post Covid-19 neurological syndrome (PCNS) patient. Brain Sci. 2021;11:454. doi: 10.3390/brainsci11040454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11040454</ArticleId><ArticleId IdType="pmc">PMC8066611</ArticleId><ArticleId IdType="pubmed">33918426</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakhmola S., Indari O., Chatterjee S., Jha H.C. SARS-CoV-2, an underestimated pathogen of the nervous system. SN Compr. Clin. Med. 2020;2:2137&#x2013;2146. doi: 10.1007/s42399-020-00522-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00522-7</ArticleId><ArticleId IdType="pmc">PMC7520376</ArticleId><ArticleId IdType="pubmed">33015550</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J., Gong E., Zhang B., Zheng J., Gao Z., Zhong Y., Zou W., Zhan J., Wang S., Xie Z., et al. Multiple organ infection and the pathogenesis of SARS. J. Exp. Med. 2005;202:415&#x2013;424. doi: 10.1084/jem.20050828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050828</ArticleId><ArticleId IdType="pmc">PMC2213088</ArticleId><ArticleId IdType="pubmed">16043521</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Saiegh F., Ghosh R., Leibold A., Avery M.B., Schmidt R.F., Theofanis T., Miuchtouris N., Philipp L., Peiper S.C., Wang Z.-X. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. J. Neurol. Neurosurg. Psychiatry. 2020;91:846&#x2013;848. doi: 10.1136/jnnp-2020-323522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323522</ArticleId><ArticleId IdType="pubmed">32354770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair A.S., Mcalpine L.S., Gardin T., Farhadian S., Kuruvilla D.E., Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurol. 2020;77:1018&#x2013;1027. doi: 10.1001/jamaneurol.2020.2065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.2065</ArticleId><ArticleId IdType="pmc">PMC7484225</ArticleId><ArticleId IdType="pubmed">32469387</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuzzo D., Picone P. Potential neurological effects of severe COVID-19 infection. Neurosci. Res. 2020;158:1&#x2013;5. doi: 10.1016/j.neures.2020.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7333632</ArticleId><ArticleId IdType="pubmed">32628969</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C., Anrather J., Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16&#x2013;27. doi: 10.1016/j.cell.2020.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.028</ArticleId><ArticleId IdType="pmc">PMC7437501</ArticleId><ArticleId IdType="pubmed">32882182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco-Herrero M., Soto-Rojas L.O., Harrington C.R., Flores-Martinez Y.M., Villegas-Rojas M.M., Le&#xf3;n-Aguilar A.M., Mart&#xed;nez-G&#xf3;mez P.A., Campa-C&#xf3;rdoba B.B., Ap&#xe1;tiga-P&#xe9;rez R., Corniel-Taveras C.N., et al. Elucidating the neuropathologic mechanisms of SARS-CoV-2 infection. Front. Neurol. 2021;12:660087. doi: 10.3389/fneur.2021.660087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.660087</ArticleId><ArticleId IdType="pmc">PMC8072392</ArticleId><ArticleId IdType="pubmed">33912129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dziedzic A., Saluk-Bijak J., Miller E., Niemcewicz M., Bijak M. The impact of SARS-CoV-2 infection on the development of neurodegeneration in multiple sclerosis. Int. J. Mol. Sci. 2021;22:1804. doi: 10.3390/ijms22041804.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041804</ArticleId><ArticleId IdType="pmc">PMC7918534</ArticleId><ArticleId IdType="pubmed">33670394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry Z.L., Klenja D., Janjua N., Cami-Kobeci G., Ahmed B.Y. COVID-19 and Parkinson&#x2019;s disease: Shared inflammatory pathways under oxidative stress. Brain Sci. 2020;10:807. doi: 10.3390/brainsci10110807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci10110807</ArticleId><ArticleId IdType="pmc">PMC7693814</ArticleId><ArticleId IdType="pubmed">33142819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan&#xe1;-Cuevas P., Salles-G&#xe1;ndara P., Rojas-Fernandez A., Salinas-Rebolledo C., Mil&#xe1;n-Sol&#xe9; A. The potential role of SARS-COV-2 in the pathogenesis of Parkinson&#x2019;s disease. Front. Neurol. 2020;11:1044. doi: 10.3389/fneur.2020.01044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.01044</ArticleId><ArticleId IdType="pmc">PMC7527541</ArticleId><ArticleId IdType="pubmed">33041985</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate G., Memo M., Uberti D. Impact of COVID-19 on Alzheimer&#x2019;s disease risk: Viewpoint for research action. Healthcare. 2020;8:30286. doi: 10.3390/healthcare8030286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare8030286</ArticleId><ArticleId IdType="pmc">PMC7551579</ArticleId><ArticleId IdType="pubmed">32839380</ArticleId></ArticleIdList></Reference><Reference><Citation>Varahachalam S.P., Lahooti B., Chamaneh M., Bagchi S., Chhibber T., Morris K., Bolanos J.F., Kim N.Y., Kaushik A. Nanomedicine for the SARS-CoV-2: State-of-the-art and future prospects. Int. J. Nanomed. 2021;16:539&#x2013;560. doi: 10.2147/IJN.S283686.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S283686</ArticleId><ArticleId IdType="pmc">PMC7837559</ArticleId><ArticleId IdType="pubmed">33519200</ArticleId></ArticleIdList></Reference><Reference><Citation>Saravanan M., Mostafavi E., Vincent S., Negash H., Andavar R., Perumal V., Barabadi H. Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19. Microb. Pathog. 2021;156:104908. doi: 10.1016/j.micpath.2021.104908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104908</ArticleId><ArticleId IdType="pmc">PMC8079947</ArticleId><ArticleId IdType="pubmed">33932543</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J.L., Morstorf T., Zhong K. Alzheimer&#x2019;s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer Res. Ther. 2014;6:37. doi: 10.1186/alzrt269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt269</ArticleId><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti P., Manna J., Dunbar G.L. Current understanding of the molecular mechanisms in Parkinson&#x2019;s disease: Targets for potential treatments. Transl. Neurodegener. 2017;6:28. doi: 10.1186/s40035-017-0099-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0099-z</ArticleId><ArticleId IdType="pmc">PMC5655877</ArticleId><ArticleId IdType="pubmed">29090092</ArticleId></ArticleIdList></Reference><Reference><Citation>Capriotti T., Terzakis K. Parkinson disease. Home Healthc. Now. 2016;34:300&#x2013;307. doi: 10.1097/NHH.0000000000000398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NHH.0000000000000398</ArticleId><ArticleId IdType="pubmed">27243427</ArticleId></ArticleIdList></Reference><Reference><Citation>Asil S.M., Ahlawat J., Barroso G.G., Narayan M. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomater. Sci. 2020;8:4109&#x2013;4128. doi: 10.1039/D0BM00809E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0BM00809E</ArticleId><ArticleId IdType="pmc">PMC7439575</ArticleId><ArticleId IdType="pubmed">32638706</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaghue I.E., Tam R., Sefton M.V., Shoichet M.S. Cell and biomolecule delivery for tissue repair and regeneration in the central nervous system. J. Control. Release. 2014;190:219&#x2013;227. doi: 10.1016/j.jconrel.2014.05.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2014.05.040</ArticleId><ArticleId IdType="pubmed">24878181</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova A., Angelov B. Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair. Neural Regen. Res. 2017;12:886&#x2013;889. doi: 10.4103/1673-5374.208546.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.208546</ArticleId><ArticleId IdType="pmc">PMC5514857</ArticleId><ArticleId IdType="pubmed">28761415</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K.H., Riaz M.K., Xie Y., Zhang X., Liu Q., Chen H., Bian Z., Chen X., Lu A., Yang Z. Review of current strategies for delivering Alzheimer&#x2019;s disease drugs across the blood-brain barrier. Int. J. Mol. Sci. 2019;20:381. doi: 10.3390/ijms20020381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020381</ArticleId><ArticleId IdType="pmc">PMC6358942</ArticleId><ArticleId IdType="pubmed">30658419</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;ral C., Angelova A., Lesieur S. From molecular to nanotechnology strategies for delivery of neurotrophins: Emphasis on brain-derived neurotrophic factor (BDNF) Pharmaceutics. 2013;5:127&#x2013;167. doi: 10.3390/pharmaceutics5010127.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics5010127</ArticleId><ArticleId IdType="pmc">PMC3834942</ArticleId><ArticleId IdType="pubmed">24300402</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova A., Angelov B., Drechsler M., Lesieur S. Neurotrophin delivery using nanotechnology. Drug Discov. Today. 2013;18:1263&#x2013;1271. doi: 10.1016/j.drudis.2013.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2013.07.010</ArticleId><ArticleId IdType="pubmed">23891881</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen H.J., Saarma M. CDNF protein therapy in Parkinson&#x2019;s disease. Cell Transpl. 2019;28:349&#x2013;366. doi: 10.1177/0963689719840290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0963689719840290</ArticleId><ArticleId IdType="pmc">PMC6628563</ArticleId><ArticleId IdType="pubmed">30947516</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbiah R., Guldberg R.E. Materials science and design principles of growth factor delivery systems in tissue engineering and regenerative medicine. Adv. Healthc. Mater. 2019;8:e1801000. doi: 10.1002/adhm.201801000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.201801000</ArticleId><ArticleId IdType="pubmed">30398700</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferenz K.B., Gast R.E., Rose K., Finger I.E., Hasche A., Krieglstein J. Nerve growth factor and brain-derived neurotrophic factor but not granulocyte colony-stimulating factor, nimodipine and dizocilpine, require ATP for neuroprotective activity after oxygen&#x2013;glucose deprivation of primary neurons. Brain Res. 2012;1448:20&#x2013;26. doi: 10.1016/j.brainres.2012.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.02.016</ArticleId><ArticleId IdType="pubmed">22386494</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi-Montalcini R. Growth control of nerve cells by a protein factor and its antiserum: Discovery of this factor may provide new leads to understanding of some neurogenetic processes. Science. 1964;143:105&#x2013;110. doi: 10.1126/science.143.3602.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.143.3602.105</ArticleId><ArticleId IdType="pubmed">14075717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanova L., Karelson M., Dobchev D.A. Identification of natural compounds against neurodegenerative diseases using in silico techniques. Molecules. 2018;23:1847. doi: 10.3390/molecules23081847.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23081847</ArticleId><ArticleId IdType="pmc">PMC6222649</ArticleId><ArticleId IdType="pubmed">30044400</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Hudalla G.A. Using self-assembling peptides to integrate biomolecules into functional supramolecular biomaterials. Molecules. 2019;24:1450. doi: 10.3390/molecules24081450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24081450</ArticleId><ArticleId IdType="pmc">PMC6514692</ArticleId><ArticleId IdType="pubmed">31013712</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash A., Medhi B., Chopra K. Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-&#x3b2; induced experimental model of Alzheimer&#x2019;s disease. Pharm. Biochem Behav. 2013;110:46&#x2013;57. doi: 10.1016/j.pbb.2013.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2013.05.015</ArticleId><ArticleId IdType="pubmed">23756182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucini C., D&#x2019;Angelo L., Cacialli P., Palladino A., De Girolamo P. BDNF, brain, and regeneration: Insights from zebrafish. Int. J. Mol. Sci. 2018;19:3155. doi: 10.3390/ijms19103155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19103155</ArticleId><ArticleId IdType="pmc">PMC6214035</ArticleId><ArticleId IdType="pubmed">30322169</ArticleId></ArticleIdList></Reference><Reference><Citation>Numakawa T., Odaka H., Adachi N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int. J. Mol. Sci. 2018;19:3650. doi: 10.3390/ijms19113650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19113650</ArticleId><ArticleId IdType="pmc">PMC6274766</ArticleId><ArticleId IdType="pubmed">30463271</ArticleId></ArticleIdList></Reference><Reference><Citation>Runeberg-Roos P., Piccinini E., Penttinen A.M., M&#xe4;tlik K., Heikkinen H., Kuure S., Bespalov M.M., Per&#xe4;nen J., Garea-Rodr&#xed;guez E., Fuchs E., et al. Developing therapeutically more efficient neurturin variants for treatment of Parkinson&#x2019;s disease. Neurobiol. Dis. 2016;96:335&#x2013;345. doi: 10.1016/j.nbd.2016.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.008</ArticleId><ArticleId IdType="pubmed">27425888</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher J.L., Murray S.S., Xiao J. Brain-derived neurotrophin factor in central nervous system nyelination: A New mechanism to promote myelin plasticity and repair. Int. J. Mol. Sci. 2018;19:4131. doi: 10.3390/ijms19124131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19124131</ArticleId><ArticleId IdType="pmc">PMC6321406</ArticleId><ArticleId IdType="pubmed">30572673</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan A.M., Toulouse A. Neurotrophic factors for the treatment of Parkinson&#x2019;s disease. Cytokine Growth Factor Rev. 2011;22:157&#x2013;165. doi: 10.1016/j.cytogfr.2011.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2011.05.001</ArticleId><ArticleId IdType="pubmed">21689963</ArticleId></ArticleIdList></Reference><Reference><Citation>Aron L., Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci. 2011;34:88&#x2013;100. doi: 10.1016/j.tins.2010.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2010.11.001</ArticleId><ArticleId IdType="pubmed">21144600</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul G., Zachrisson O., Varrone A., Almqvist P., Jerling M., Lind G., Rehncrona S., Linderoth B., Bjartmarz H., Shafer L.L., et al. Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson&#x2019;s disease patients. J. Clin. Investig. 2015;125:1339&#x2013;1346. doi: 10.1172/JCI79635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI79635</ArticleId><ArticleId IdType="pmc">PMC4362250</ArticleId><ArticleId IdType="pubmed">25689258</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadana D., Adamcik J., Ryan T.M., Appiah Danso S., Chong C.J.H., Conn C.E., Reynolds N.P., Mezzenga R., Val&#xe9;ry C. Peptide substance P self-assembles into semi-flexible nanotubes that can be manipulated for nanotechnology. Nanoscale. 2020;12:22680&#x2013;22687. doi: 10.1039/D0NR05622G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0NR05622G</ArticleId><ArticleId IdType="pubmed">33165459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xe4;bitz W.R., Kr&#xfc;ger C., Pitzer C., Weber D., Laage R., Gassler N., Aronowski J., Mier W., Kirsch F., Dittgen T., et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF) J. Cereb. Blood Flow Metab. 2008;28:29&#x2013;43. doi: 10.1038/sj.jcbfm.9600496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600496</ArticleId><ArticleId IdType="pubmed">17457367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi V.E., Locatelli V., Rizzi L. Neurotrophic and neuroregenerative effects of GH/IGF1. Int. J. Mol. Sci. 2017;18:2441. doi: 10.3390/ijms18112441.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18112441</ArticleId><ArticleId IdType="pmc">PMC5713408</ArticleId><ArticleId IdType="pubmed">29149058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan K., Das G., Gupta V., Mondal P., Barman S., Khan J., Ghosh S. Discovery of neuroregenerative peptoid from amphibian neuropeptide that inhibits amyloid-&#x3b2; toxicity and crosses blood-brain barrier. ACS Chem. Neurosci. 2019;10:1355&#x2013;1368. doi: 10.1021/acschemneuro.8b00427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00427</ArticleId><ArticleId IdType="pubmed">30408415</ArticleId></ArticleIdList></Reference><Reference><Citation>Chermenina M., Schouten P., Nevalainen N., Johansson F., Or&#xe4;dd G., Str&#xf6;mberg I. GDNF is important for striatal organization and maintenance of dopamine neurons grown in the presence of the striatum. Neuroscience. 2014;270:1&#x2013;11. doi: 10.1016/j.neuroscience.2014.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2014.04.008</ArticleId><ArticleId IdType="pubmed">24726488</ArticleId></ArticleIdList></Reference><Reference><Citation>Grondin R., Littrell O.M., Zhang Z., Ai Y., Huettl P., Pomerleau F., Quintero J.E., Andersen A.H., Stenslik M.J., Bradley L.H., et al. GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution. Neuropharmacology. 2019;147:28&#x2013;36. doi: 10.1016/j.neuropharm.2018.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2018.05.014</ArticleId><ArticleId IdType="pubmed">29857941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez C.F., Andressoo J.O. Biology of GDNF and its receptors&#x2014;Relevance for disorders of the central nervous system. Neurobiol. Dis. 2017;97:80&#x2013;89. doi: 10.1016/j.nbd.2016.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.01.021</ArticleId><ArticleId IdType="pubmed">26829643</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.C., O&#x2019;Bryan L.M., Mitchell P.J., Leung D., Ghanem M., Wilson J.M., Hanson J.C., Sossick S., Cooper J., Huang L., et al. Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF. Exp. Neurol. 2015;267:165&#x2013;176. doi: 10.1016/j.expneurol.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.03.002</ArticleId><ArticleId IdType="pubmed">25771799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai K.J., Tsai Y.C., Shen C.K. G-CSF rescues the memory impairment of animal models of Alzheimer&#x2019;s disease. J. Exp. Med. 2007;204:1273&#x2013;1280. doi: 10.1084/jem.20062481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062481</ArticleId><ArticleId IdType="pmc">PMC2118601</ArticleId><ArticleId IdType="pubmed">17517969</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramos J., Song S., Sava V., Catlow B., Lin X., Mori T., Cao C., Arendash G.W. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer&#x2019;s mice. Neuroscience. 2009;163:55&#x2013;72. doi: 10.1016/j.neuroscience.2009.05.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.05.071</ArticleId><ArticleId IdType="pmc">PMC5966834</ArticleId><ArticleId IdType="pubmed">19500657</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A., Kr&#xfc;ger C., Steigleder T., Weber D., Pitzer C., Laage R., Aronowski J., Maurer M.H., Gassler N., Mier W., et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J. Clin. Investig. 2005;115:2083&#x2013;2098. doi: 10.1172/JCI23559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI23559</ArticleId><ArticleId IdType="pmc">PMC1172228</ArticleId><ArticleId IdType="pubmed">16007267</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., Lozano A.M., Penn R.D., Simpson R.K., Stacy M., et al. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69&#x2013;73. doi: 10.1212/WNL.60.1.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.60.1.69</ArticleId><ArticleId IdType="pubmed">12525720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill S.S., Patel N.K., Hotton G.R., O&#x2019;Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003;9:589&#x2013;595. doi: 10.1038/nm850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm850</ArticleId><ArticleId IdType="pubmed">12669033</ArticleId></ArticleIdList></Reference><Reference><Citation>Whone A., Luz M., Boca M., Woolley M., Mooney L., Dharia S., Broadfoot J., Cronin D., Schroers C., Barua N.U., et al. Randomized trial of intermittent intraputamenal glial cell linederived neurotrophic factor in Parkinson&#x2019;s disease. Brain. 2019;142:512&#x2013;525. doi: 10.1093/brain/awz023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz023</ArticleId><ArticleId IdType="pmc">PMC6391602</ArticleId><ArticleId IdType="pubmed">30808022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishna S., Muddashetty R.S. Emerging role of microRNAs in dementia. J. Mol. Biol. 2019;431:1743&#x2013;1762. doi: 10.1016/j.jmb.2019.01.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.01.046</ArticleId><ArticleId IdType="pubmed">30738891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Ge X., Chen Y., Lv N., Liu Z., Yuan W. Advances with RNA interference in Alzheimer&#x2019;s disease research. Drug Des. Devel. Ther. 2013;7:117&#x2013;125. doi: 10.2147/DDDT.S40229.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S40229</ArticleId><ArticleId IdType="pmc">PMC3582316</ArticleId><ArticleId IdType="pubmed">23459401</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller V.M., Gouvion C.M., Davidson B.L., Paulson H.L. Targeting Alzheimer&#x2019;s disease genes with RNA interference: An efficient strategy for silencing mutant alleles. Nucleic Acids Res. 2004;32:661&#x2013;668. doi: 10.1093/nar/gkh208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh208</ArticleId><ArticleId IdType="pmc">PMC373334</ArticleId><ArticleId IdType="pubmed">14754988</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegarty S.V., Lee D.J., O&#x2019;Keeffe G.W., Sullivan A.M. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson&#x2019;s disease: A systematic review and meta-analysis. Parkinsonism Relat. Disord. 2017;38:19&#x2013;25. doi: 10.1016/j.parkreldis.2017.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2017.02.011</ArticleId><ArticleId IdType="pubmed">28215730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Z., Yan Z., He R., Pang Z., Guo L., Qian Y., Jiang X., Fang L. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv. 2011;18:555&#x2013;561. doi: 10.3109/10717544.2011.596583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10717544.2011.596583</ArticleId><ArticleId IdType="pubmed">21812752</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Su J., Kamal Z., Guo P., Wu X., Lu L., Wu H., Qiu M. Odorranalectin modified PEG-PLGA/PEG-PBLG curcumin-loaded nanoparticle for intranasal administration. Drug Dev. Ind. Pharm. 2020;46:899&#x2013;909. doi: 10.1080/03639045.2020.1762202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03639045.2020.1762202</ArticleId><ArticleId IdType="pubmed">32375569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahirrao M., Shrotriya S. In vitro and in vivo evaluation of cubosomal in situ nasal gel containing resveratrol for brain targeting. Drug Dev. Ind. Pharm. 2017;43:1686&#x2013;1693. doi: 10.1080/03639045.2017.1338721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03639045.2017.1338721</ArticleId><ArticleId IdType="pubmed">28574732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Li J., Zhang Q., Yan X., Guo L., Gao X., Qiu M., Jiang X., Lai R., Chen H. A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid-&#x3b2;&#x2082;&#x2085;&#x208b;&#x2083;&#x2085;-treated rats following intranasal administration. Eur. J. Pharm. Biopharm. 2012;80:368&#x2013;378. doi: 10.1016/j.ejpb.2011.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2011.10.012</ArticleId><ArticleId IdType="pubmed">22061263</ArticleId></ArticleIdList></Reference><Reference><Citation>Erd&#x151; F., Bors L.A., Farkas D., Bajza &#xc1;., Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018;143:155&#x2013;170. doi: 10.1016/j.brainresbull.2018.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.10.009</ArticleId><ArticleId IdType="pubmed">30449731</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaridou E., Alonso M.J. Nose-to-brain peptide delivery&#x2014;The potential of nanotechnology. Bioorg. Med. Chem. 2018;26:2888&#x2013;2905. doi: 10.1016/j.bmc.2017.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2017.11.001</ArticleId><ArticleId IdType="pubmed">29170026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajja R.K., Cudic P., Cucullo L. In vitro characterization of odorranalectin for peptide-based drug delivery across the blood-brain barrier. BMC Neurosci. 2019;20:22. doi: 10.1186/s12868-019-0504-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-019-0504-x</ArticleId><ArticleId IdType="pmc">PMC6505199</ArticleId><ArticleId IdType="pubmed">31068126</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Chen M., Zhang J., Maincent P., Xia X., Wu W. Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases. Crit. Rev. Ther. Drug Carr. Syst. 2018;35:433&#x2013;467. doi: 10.1615/CritRevTherDrugCarrierSyst.2018024697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevTherDrugCarrierSyst.2018024697</ArticleId><ArticleId IdType="pubmed">30317945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 2012;64:614&#x2013;628. doi: 10.1016/j.addr.2011.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2011.11.002</ArticleId><ArticleId IdType="pubmed">22119441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lochhead J.J., Wolak D.J., Pizzo M.E., Thorne R.G. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J. Cereb. Blood Flow Metab. 2015;35:371&#x2013;381. doi: 10.1038/jcbfm.2014.215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2014.215</ArticleId><ArticleId IdType="pmc">PMC4348383</ArticleId><ArticleId IdType="pubmed">25492117</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcal&#xe1;-Barraza S.R., Lee M.S., Hanson L.R., McDonald A.A., Frey W.H., McLoon L.K. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target. 2010;18:179&#x2013;190. doi: 10.3109/10611860903318134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10611860903318134</ArticleId><ArticleId IdType="pmc">PMC3732751</ArticleId><ArticleId IdType="pubmed">19807216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D., Cederfj&#xe4;ll E., Halliday G., Peters&#xe9;n &#xc5;. Gene therapy for Parkinson&#x2019;s disease: Disease modification by GDNF family of ligands. Neurobiol. Dis. 2017;97 Pt B:179&#x2013;188. doi: 10.1016/j.nbd.2016.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.09.008</ArticleId><ArticleId IdType="pubmed">27616425</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J.Y., Yang K.J., Park S.N., Kim D.K., Kim J.D. The effect of dexamethasone/cell-penetrating peptide nanoparticles on gene delivery for inner ear therapy. Int. J. Nanomed. 2016;11:6123&#x2013;6134. doi: 10.2147/IJN.S114241.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S114241</ArticleId><ArticleId IdType="pmc">PMC5117898</ArticleId><ArticleId IdType="pubmed">27895484</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus R.T., Baumann T.L., Siffert J., Herzog C.D., Alterman R., Boulis N., Turner D.A., Stacy M., Lang A.E., Lozano A.M., et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 2013;80:1698&#x2013;1701. doi: 10.1212/WNL.0b013e3182904faa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182904faa</ArticleId><ArticleId IdType="pmc">PMC3716474</ArticleId><ArticleId IdType="pubmed">23576625</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks W.J., Jr., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#x2019;s disease: An open-label, phase I trial. Lancet Neurol. 2008;7:400&#x2013;408. doi: 10.1016/S1474-4422(08)70065-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70065-6</ArticleId><ArticleId IdType="pubmed">18387850</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks W.J., Jr., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., et al. Gene delivery of AAV2-neurturin for Parkinson&#x2019;s disease: A double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:1164&#x2013;1172. doi: 10.1016/S1474-4422(10)70254-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70254-4</ArticleId><ArticleId IdType="pubmed">20970382</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson R.T., Wise A.K., Thompson B.C., Flynn B.O., Atkinson P.J., Fretwell N.J., Fallon J.B., Wallace G.G., Shepherd R.K., Clark G.M., et al. Polypyrrole-coated electrodes for the delivery of charge and neurotrophins to cochlear neurons. Biomaterials. 2009;30:2614&#x2013;2624. doi: 10.1016/j.biomaterials.2009.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2009.01.015</ArticleId><ArticleId IdType="pmc">PMC3563695</ArticleId><ArticleId IdType="pubmed">19178943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikkawa Y.S., Nakagawa T., Ying L., Tabata Y., Tsubouchi H., Ido A., Ito J. Growth factor-eluting cochlear implant electrode: Impact on residual auditory function, insertional trauma, and fibrosis. J. Transl. Med. 2014;12:280. doi: 10.1186/s12967-014-0280-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-014-0280-4</ArticleId><ArticleId IdType="pmc">PMC4189752</ArticleId><ArticleId IdType="pubmed">25280483</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikar J.A., Hendricks J.L., Richardson-Burns S.M., Raphael Y., Pfingst B.E., Martin D.C. The use of a dual PEDOT and RGD-functionalized alginate hydrogel coating to provide sustained drug delivery and improved cochlear implant function. Biomaterials. 2012;33:1982&#x2013;1990. doi: 10.1016/j.biomaterials.2011.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.11.052</ArticleId><ArticleId IdType="pmc">PMC3261353</ArticleId><ArticleId IdType="pubmed">22182748</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo T., Nakagawa T., Kita T., Iguchi F., Kim T.S., Tamura T., Iwai K., Tabata Y., Ito J. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope. 2005;115:2016&#x2013;2020. doi: 10.1097/01.mlg.0000183020.32435.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mlg.0000183020.32435.59</ArticleId><ArticleId IdType="pubmed">16319616</ArticleId></ArticleIdList></Reference><Reference><Citation>Madduri S., Gander B. Growth factor delivery systems and repair strategies for damaged peripheral nerves. J. Control. Release. 2012;161:274&#x2013;282. doi: 10.1016/j.jconrel.2011.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2011.11.036</ArticleId><ArticleId IdType="pubmed">22178593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wise A.K., Tan J., Maina J.W., Shepherd R.K., Caruso F. Mesoporous silica supraparticles for sustained inner-ear drug delivery. Small. 2014;10:4244&#x2013;4248. doi: 10.1002/smll.201470132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.201470132</ArticleId><ArticleId IdType="pubmed">25099026</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Edin F., Hayashi H., Gudjonsson O., Danckwardt-Lilliestr&#xf6;m N., Engqvist H., Rask-Andersen H., Xia W. Guided growth of auditory neurons: Bioactive particles towards gapless neural-electrode interface. Biomaterials. 2017;122:1&#x2013;9. doi: 10.1016/j.biomaterials.2016.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2016.12.020</ArticleId><ArticleId IdType="pubmed">28107660</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S., Glueckert R., Johnston A.H., Perrier T., Bitsche M., Newman T.A., Saulnier P., Schrott-Fischer A. Strategies for drug delivery to the human inner ear by multifunctional nanoparticles. Nanomedicine. 2012;7:55&#x2013;63. doi: 10.2217/nnm.11.84.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm.11.84</ArticleId><ArticleId IdType="pubmed">22106854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra S., Behbahani H., Eriksdotter M. Innovative therapy for Alzheimer&#x2019;s disease with focus on biodelivery of NGF. Front. Neurosci. 2019;13:38. doi: 10.3389/fnins.2019.00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00038</ArticleId><ArticleId IdType="pmc">PMC6370742</ArticleId><ArticleId IdType="pubmed">30804738</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Y., Chen Y., Jin Y., Han G., Song M., Song T., Shi Y., Tao L., Huang Z., Zhou J., et al. Versatile nanomaterials for Alzheimer&#x2019;s disease: Pathogenesis inspired disease-modifying therapy. J. Control Release. 2022;345:38. doi: 10.1016/j.jconrel.2022.02.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.02.034</ArticleId><ArticleId IdType="pubmed">35257810</ArticleId></ArticleIdList></Reference><Reference><Citation>Akel H., Ismail R., Cs&#xf3;ka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer&#x2019;s disease. Eur. J. Pharm. Biopharm. 2020;148:38&#x2013;53. doi: 10.1016/j.ejpb.2019.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2019.12.014</ArticleId><ArticleId IdType="pubmed">31926222</ArticleId></ArticleIdList></Reference><Reference><Citation>Babazadeh A., Mohammadi Vahed F., Jafari S.M. Nanocarrier-mediated brain delivery of bioactives for treatment/prevention of neurodegenerative diseases. J. Control. Release. 2020;321:211&#x2013;221. doi: 10.1016/j.jconrel.2020.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.02.015</ArticleId><ArticleId IdType="pubmed">32035189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonvico F., Clementino A., Buttini F., Colombo G., Pescina S., Stanis&#xe7;uaski Guterres S., Raffin Pohlmann A., Nicoli S. Surface-modified nanocarriers for nose-to-brain delivery: From bioadhesion to targeting. Pharmaceutics. 2018;10:34. doi: 10.3390/pharmaceutics10010034.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics10010034</ArticleId><ArticleId IdType="pmc">PMC5874847</ArticleId><ArticleId IdType="pubmed">29543755</ArticleId></ArticleIdList></Reference><Reference><Citation>Jao D., Xue Y., Medina J., Hu X. Protein-based drug-delivery materials. Materials. 2017;10:517. doi: 10.3390/ma10050517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma10050517</ArticleId><ArticleId IdType="pmc">PMC5459032</ArticleId><ArticleId IdType="pubmed">28772877</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith M., Abramovitz L., Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano. 2014;8:1958&#x2013;1965. doi: 10.1021/nn501292z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn501292z</ArticleId><ArticleId IdType="pubmed">24660817</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrahari V., Burnouf P.A., Burnouf T., Agrahari V. Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Adv. Drug Deliv. Rev. 2019;148:146&#x2013;180. doi: 10.1016/j.addr.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2019.02.008</ArticleId><ArticleId IdType="pubmed">30797956</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira M.I., Lopes C.M., Amaral M.H., Costa P.C. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur. J. Pharm. Biopharm. 2020;149:192&#x2013;217. doi: 10.1016/j.ejpb.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2020.01.005</ArticleId><ArticleId IdType="pubmed">31982574</ArticleId></ArticleIdList></Reference><Reference><Citation>Harilal S., Jose J., Parambi D.G.T., Kumar R., Mathew G.E., Uddin M.S., Kim H., Mathew B. Advancements in nanotherapeutics for Alzheimer&#x2019;s disease: Current perspectives. J. Pharm. Pharmacol. 2019;71:1370&#x2013;1383. doi: 10.1111/jphp.13132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jphp.13132</ArticleId><ArticleId IdType="pubmed">31304982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorkina Y., Abramova O., Ushakova V., Morozova A., Zubkov E., Valikhov M., Melnikov P., Majouga A., Chekhonin V. Nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: Advantages and limitations. Molecules. 2020;25:5294. doi: 10.3390/molecules25225294.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25225294</ArticleId><ArticleId IdType="pmc">PMC7697162</ArticleId><ArticleId IdType="pubmed">33202839</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokel R.A. Nanoparticle brain delivery: A guide to verification methods. Nanomedicine. 2020;15:409&#x2013;432. doi: 10.2217/nnm-2019-0169.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2019-0169</ArticleId><ArticleId IdType="pubmed">31999236</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen M.M., El-Salamouni N.S., El-Refaie W.M., Hazzah H.A., Ali M.M., Tosi G., Farid R.M., Blanco-Prieto M.J., Billa N., Hanafy A.S. Nanotechnology-based drug delivery systems for Alzheimer&#x2019;s disease management: Technical, industrial, and clinical challenges. J. Control. Release. 2017;245:95&#x2013;107. doi: 10.1016/j.jconrel.2016.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.11.025</ArticleId><ArticleId IdType="pubmed">27889394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahni J.K., Doggui S., Ali J., Baboota S., Dao L., Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer&#x2019;s disease. J. Control. Release. 2011;152:208&#x2013;231. doi: 10.1016/j.jconrel.2010.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2010.11.033</ArticleId><ArticleId IdType="pubmed">21134407</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla D., Le Droumaguet B., Nicolas J., Hashemi S.H., Wu L.P., Moghimi S.M., Couvreur P., Andrieux K. Nanotechnologies for Alzheimer&#x2019;s disease: Diagnosis, therapy, and safety issues. Nanomedicine. 2011;7:521&#x2013;540. doi: 10.1016/j.nano.2011.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2011.03.008</ArticleId><ArticleId IdType="pubmed">21477665</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi M., Eslamifar M., Khezri K., Dizaj S.M. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharm. 2019;111:666&#x2013;675. doi: 10.1016/j.biopha.2018.12.133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.12.133</ArticleId><ArticleId IdType="pubmed">30611991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires P.C., Santos A.O. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J. Control. Release. 2018;270:89&#x2013;100. doi: 10.1016/j.jconrel.2017.11.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.11.047</ArticleId><ArticleId IdType="pubmed">29199063</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;ral C., Angelova A., Angelov B., Nicolas V., Lesieur S. Chapter 11: Multicompartment lipid nanocarriers for targeting of cells expressing brain receptors. In: Garti N., Mezzenga R., Somasundaran P., editors. Self-Assembled Supramolecular Architectures: Lyotropic Liquid Crystals. John Wiley &amp; Sons, Inc.; New Jersey, NJ, USA: 2012. pp. 319&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9781118336632.ch11</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw K., Zhang Z., Kannan S. Neuronanotechnology for brain regeneration. Adv. Drug Deliv. Rev. 2019;148:3&#x2013;18. doi: 10.1016/j.addr.2019.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2019.04.004</ArticleId><ArticleId IdType="pubmed">31668648</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liu C. Nanomaterial-based bone regeneration. Nanoscale. 2017;9:4862&#x2013;4874. doi: 10.1039/C7NR00835J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7NR00835J</ArticleId><ArticleId IdType="pubmed">28358401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu M., Tang J., Wei Y., Sun Y., Wang X., Wu L., Liu H. Enhanced bioavailability of nerve growth factor with phytantriol lipid-based crystalline nanoparticles in cochlea. Int. J. Nanomed. 2015;10:6879&#x2013;6889. doi: 10.2147/IJN.S82944.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S82944</ArticleId><ArticleId IdType="pmc">PMC4639561</ArticleId><ArticleId IdType="pubmed">26604754</ArticleId></ArticleIdList></Reference><Reference><Citation>Guccione C., Oufir M., Piazzini V., Eigenmann D.E., J&#xe4;hne E.A., Zabela V., Faleschini M.T., Bergonzi M.C., Smiesko M., Hamburger M., et al. Andrographolide-loaded nanoparticles for brain delivery: Formulation, characterisation and in vitro permeability using hCMEC/D3 cell line. Eur. J. Pharm. Biopharm. 2017;119:253&#x2013;263. doi: 10.1016/j.ejpb.2017.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2017.06.018</ArticleId><ArticleId IdType="pubmed">28652141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva C., Pra&#xe7;a C., Ferreira R., Santos T., Ferreira L., Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J. Control. Release. 2016;235:34&#x2013;47. doi: 10.1016/j.jconrel.2016.05.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.05.044</ArticleId><ArticleId IdType="pubmed">27208862</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T.T., Li W., Meng G., Wang P., Liao W. Strategies for transporting nanoparticles across the blood-brain barrier. Biomater. Sci. 2016;4:219&#x2013;229. doi: 10.1039/C5BM00383K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5BM00383K</ArticleId><ArticleId IdType="pubmed">26646694</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal M., Ajazuddin Tripathi D.K., Saraf S., Saraf S., Antimisiaris S.G., Mourtas S., Hammarlund-Udenaes M., Alexander A. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer&#x2019;s disease. J. Control. Release. 2017;260:61&#x2013;77. doi: 10.1016/j.jconrel.2017.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.05.019</ArticleId><ArticleId IdType="pubmed">28549949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma G., Sharma A.R., Lee S.S., Bhattacharya M., Nam J.S., Chakraborty C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int. J. Pharm. 2019;559:360&#x2013;372. doi: 10.1016/j.ijpharm.2019.01.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2019.01.056</ArticleId><ArticleId IdType="pubmed">30721725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Ahn S.I., Kim Y. Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system. J. Ind. Eng. Chem. 2019;73:8&#x2013;18. doi: 10.1016/j.jiec.2019.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiec.2019.01.021</ArticleId><ArticleId IdType="pmc">PMC6777578</ArticleId><ArticleId IdType="pubmed">31588177</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj R., Wairkar S., Sridhar V., Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int. J. Biol. Macromol. 2018;109:27&#x2013;35. doi: 10.1016/j.ijbiomac.2017.12.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2017.12.056</ArticleId><ArticleId IdType="pubmed">29247729</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskinazi-Budge A., Manickavasagam D., Czech T., Novak K., Kunzler J., Oyewumi M.O. Preparation of emulsifying wax/glyceryl monooleate nanoparticles and evaluation as a delivery system for repurposing simvastatin in bone regeneration. Drug Dev. Ind. Pharm. 2018;44:1583&#x2013;1590. doi: 10.1080/03639045.2018.1483381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03639045.2018.1483381</ArticleId><ArticleId IdType="pubmed">29847182</ArticleId></ArticleIdList></Reference><Reference><Citation>Elnaggar Y.S., Etman S.M., Abdelmonsif D.A., Abdallah O.Y. Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer&#x2019;s disease: Pharmaceutical, biological, and toxicological studies. Int. J. Nanomed. 2015;10:5459&#x2013;5473. doi: 10.2147/IJN.S87336.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S87336</ArticleId><ArticleId IdType="pmc">PMC4556290</ArticleId><ArticleId IdType="pubmed">26346130</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Song H., Xiong S., Tian T., Liu T., Sun Y. Chitosan-stablized bovine serum albumin nanoparticles having ability to control the release of NELL-1 protein. Int. J. Biol. Macromol. 2018;109:672&#x2013;680. doi: 10.1016/j.ijbiomac.2017.12.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2017.12.104</ArticleId><ArticleId IdType="pubmed">29288032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee B., Gorain B., Mohananaidu K., Sengupta P., Mandal U.K., Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int. J. Pharm. 2019;565:258&#x2013;268. doi: 10.1016/j.ijpharm.2019.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2019.05.032</ArticleId><ArticleId IdType="pubmed">31095983</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshiro J.A., Sato M.R., Scardueli C.R., Lopes de Oliveira G.J.P., Abucafy M.P., Chorilli M. Bioactive molecule-loaded drug delivery systems to optimize bone tissue repair. Curr. Protein Pept. Sci. 2017;18:850&#x2013;863. doi: 10.2174/1389203718666170328111605.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203718666170328111605</ArticleId><ArticleId IdType="pubmed">28355998</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E.P., Cotter J.D., Prakapenka A.V., Cook R.L., DiPerna D.M., Sirianni R.W. Targeting small molecule delivery to the brain and spinal cord via intranasal administration of Rabies Virus Glycoprotein (RVG29)-modified PLGA nanoparticles. Pharmaceutics. 2020;12:93. doi: 10.3390/pharmaceutics12020093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12020093</ArticleId><ArticleId IdType="pmc">PMC7076461</ArticleId><ArticleId IdType="pubmed">31991664</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazzini V., Landucci E., D&#x2019;Ambrosio M., Tiozzo Fasiolo L., Cinci L., Colombo G., Pellegrini-Giampietro D.E., Bilia A.R., Luceri C., Bergonzi M.C. Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery. Int. J. Biol. Macromol. 2019;129:267&#x2013;280. doi: 10.1016/j.ijbiomac.2019.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2019.02.005</ArticleId><ArticleId IdType="pubmed">30726749</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin T., Yang L., Liu Y., Zhou X., Sun J., Liu J. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer&#x2019;s disease. Acta Biomater. 2015;25:172&#x2013;183. doi: 10.1016/j.actbio.2015.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2015.06.035</ArticleId><ArticleId IdType="pubmed">26143603</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnabas W. Drug targeting strategies into the brain for treating neurological diseases. J. Neurosci. Methods. 2019;311:133&#x2013;146. doi: 10.1016/j.jneumeth.2018.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2018.10.015</ArticleId><ArticleId IdType="pubmed">30336221</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S., Xu X., Feng J., Liu M., Hu K. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. Int. J. Pharm. 2019;560:282&#x2013;293. doi: 10.1016/j.ijpharm.2019.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2019.02.012</ArticleId><ArticleId IdType="pubmed">30772458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X., Zhang C., Guo Q., Wan X., Shao X., Liu Q., Zhang Q. Dual-functional nanoparticles for precise drug delivery to Alzheimer&#x2019;s disease lesions: Targeting mechanisms, pharmacodynamics and safety. Int. J. Pharm. 2017;525:237&#x2013;248. doi: 10.1016/j.ijpharm.2017.04.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2017.04.033</ArticleId><ArticleId IdType="pubmed">28432017</ArticleId></ArticleIdList></Reference><Reference><Citation>Teleanu D.M., Negut I., Grumezescu V., Grumezescu A.M., Teleanu R.I. Nanomaterials for drug delivery to the central nervous system. Nanomaterials. 2019;9:371. doi: 10.3390/nano9030371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano9030371</ArticleId><ArticleId IdType="pmc">PMC6474019</ArticleId><ArticleId IdType="pubmed">30841578</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., Wei M., Zhang N., Li H., Tan X., Zhang Y., Zheng W. Enhanced permeability of blood-brain barrier and targeting function of brain via borneol-modified chemically solid lipid nanoparticle. Int. J. Nanomed. 2018;13:1869&#x2013;1879. doi: 10.2147/IJN.S161237.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S161237</ArticleId><ArticleId IdType="pmc">PMC5880572</ArticleId><ArticleId IdType="pubmed">29636606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Yang F., Liao Y., Li L., Zhang L. Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: In vitro and in vivo evaluations. Drug Deliv. 2017;24:121&#x2013;132. doi: 10.1080/10717544.2016.1233590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10717544.2016.1233590</ArticleId><ArticleId IdType="pmc">PMC8241168</ArticleId><ArticleId IdType="pubmed">28156159</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajbhiye K.R., Pawar A., Mahadik K.R., Gajbhiye V. PEGylated nanocarriers: A promising tool for targeted delivery to the brain. Colloids Surf. B Biointerfaces. 2020;187:110770. doi: 10.1016/j.colsurfb.2019.110770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2019.110770</ArticleId><ArticleId IdType="pubmed">31926790</ArticleId></ArticleIdList></Reference><Reference><Citation>Azhari H., Strauss M., Hook S., Boyd B.J., Rizwan S.B. Stabilising cubosomes with Tween 80 as a step towards targeting lipid nanocarriers to the blood-brain barrier. Eur. J. Pharm. Biopharm. 2016;104:148&#x2013;155. doi: 10.1016/j.ejpb.2016.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2016.05.001</ArticleId><ArticleId IdType="pubmed">27163239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobbi M., Re F., Canovi M., Beeg M., Gregori M., Sesana S., Sonnino S., Brogioli D., Musicanti C., Gasco P., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials. 2010;31:6519&#x2013;6529. doi: 10.1016/j.biomaterials.2010.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2010.04.044</ArticleId><ArticleId IdType="pubmed">20553982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Wan X., Zheng X., Shao X., Liu Q., Zhang Q., Qian Y. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer&#x2019;s disease mice. Biomaterials. 2014;35:456&#x2013;465. doi: 10.1016/j.biomaterials.2013.09.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2013.09.063</ArticleId><ArticleId IdType="pubmed">24099709</ArticleId></ArticleIdList></Reference><Reference><Citation>Aderibigbe B.A., Naki T. Chitosan-based nanocarriers for nose to brain delivery. Appl. Sci. 2019;9:2219. doi: 10.3390/app9112219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app9112219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramalho M.J., Andrade S., Loureiro J.A., do Carmo Pereira M. Nanotechnology to improve the Alzheimer&#x2019;s disease therapy with natural compounds. Drug Deliv. Transl. Res. 2020;10:380&#x2013;402. doi: 10.1007/s13346-019-00694-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-019-00694-3</ArticleId><ArticleId IdType="pubmed">31773421</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhath A., Vernekar V.N., Sanchez E., Laurencin C.T. Growth factor delivery strategies for rotator cuff repair and regeneration. Int. J. Pharm. 2018;544:358&#x2013;371. doi: 10.1016/j.ijpharm.2018.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.01.006</ArticleId><ArticleId IdType="pmc">PMC8215558</ArticleId><ArticleId IdType="pubmed">29317260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer E.A., Gottardi R., Fedorchak M.V., Little S.R. The scope and sequence of growth factor delivery for vascularized bone tissue regeneration. J. Control. Release. 2015;219:129&#x2013;140. doi: 10.1016/j.jconrel.2015.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.004</ArticleId><ArticleId IdType="pubmed">26264834</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rijt S., Habibovic P. Enhancing regenerative approaches with nanoparticles. J. R. Soc. Interface. 2017;14:20170093. doi: 10.1098/rsif.2017.0093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2017.0093</ArticleId><ArticleId IdType="pmc">PMC5414913</ArticleId><ArticleId IdType="pubmed">28404870</ArticleId></ArticleIdList></Reference><Reference><Citation>Prades R., Guerrero S., Araya E., Molina C., Salas E., Zurita E., Selva J., Egea G., L&#xf3;pez-Iglesias C., Teixid&#xf3; M., et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials. 2012;33:7194&#x2013;7205. doi: 10.1016/j.biomaterials.2012.06.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2012.06.063</ArticleId><ArticleId IdType="pubmed">22795856</ArticleId></ArticleIdList></Reference><Reference><Citation>Songjiang Z., Lixiang W. Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech. 2009;10:900&#x2013;905. doi: 10.1208/s12249-009-9279-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-009-9279-1</ArticleId><ArticleId IdType="pmc">PMC2802149</ArticleId><ArticleId IdType="pubmed">19609682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Zheng X., Wan X., Shao X., Liu Q., Zhang Z., Zhang Q. The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer&#x2019;s disease. J. Control. Release. 2014;192:317&#x2013;324. doi: 10.1016/j.jconrel.2014.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2014.07.050</ArticleId><ArticleId IdType="pubmed">25102404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Wagner S., B&#xfc;chel C., von Briesen H., Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release. 2009;137:78&#x2013;86. doi: 10.1016/j.jconrel.2009.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2009.03.002</ArticleId><ArticleId IdType="pubmed">19285109</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelov B., Angelova A., Filippov S.K., Drechsler M., &#x160;t&#x11b;p&#xe1;nek P., Lesieur S. Multicompartment lipid cubic nanoparticles with high protein upload: Millisecond dynamics of formation. ACS Nano. 2014;8:5216&#x2013;5226. doi: 10.1021/nn5012946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn5012946</ArticleId><ArticleId IdType="pubmed">24742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Wu B., Zhang Q., Chen J., Zhu J., Zhang W., Rong Z., Chen H., Jiang X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Release. 2007;121:156&#x2013;167. doi: 10.1016/j.jconrel.2007.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2007.05.026</ArticleId><ArticleId IdType="pubmed">17628165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Chen J., Feng C., Shao X., Liu Q., Zhang Q., Pang Z., Jiang X. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer&#x2019;s disease. Int. J. Pharm. 2014;461:192&#x2013;202. doi: 10.1016/j.ijpharm.2013.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2013.11.049</ArticleId><ArticleId IdType="pubmed">24300213</ArticleId></ArticleIdList></Reference><Reference><Citation>Park T.E., Singh B., Li H., Lee J.Y., Kang S.K., Choi Y.J., Cho C.S. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer&#x2019;s disease. Biomaterials. 2015;38:61&#x2013;71. doi: 10.1016/j.biomaterials.2014.10.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2014.10.068</ArticleId><ArticleId IdType="pubmed">25457984</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., An S., Li J., Kuang Y., He X., Guo Y., Ma H., Zhang Y., Ji B., Jiang C. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer&#x2019;s disease mice. Biomaterials. 2016;80:33&#x2013;45. doi: 10.1016/j.biomaterials.2015.11.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2015.11.060</ArticleId><ArticleId IdType="pubmed">26706474</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S., Sharma D., Singh J. GLUT-1: An effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier. ACS Chem. Neurosci. 2020;11:1620&#x2013;1633. doi: 10.1021/acschemneuro.0c00076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00076</ArticleId><ArticleId IdType="pubmed">32352752</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi M., Bhatt P., Chauhan G., Gupta S., Misra A., Mashru R. IGF-II-conjugated nanocarrier for brain-targeted delivery of p11 gene for depression. AAPS PharmSciTech. 2019;20:50. doi: 10.1208/s12249-018-1206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-018-1206-x</ArticleId><ArticleId IdType="pubmed">30617637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P., Zheng X., Guo Q., Yang P., Pang X., Qian K., Lu W., Zhang Q., Jiang X. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer&#x2019;s disease. J. Control. Release. 2018;279:220&#x2013;233. doi: 10.1016/j.jconrel.2018.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.04.034</ArticleId><ArticleId IdType="pubmed">29679667</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Pang Z., Ye H., Qiu B., Guo L., Li J., Ren J., Qian Y., Zhang Q., Chen J. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials. 2012;33:916&#x2013;924. doi: 10.1016/j.biomaterials.2011.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.10.035</ArticleId><ArticleId IdType="pubmed">22048008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarus D., Hamard L., Caraguel F., Wion D., Szarpak-Jankowska A., van der Sanden B., Auz&#xe9;ly-Velty R. Design of hyaluronic acid hydrogels to promote neurite outgrowth in three dimensions. ACS Appl. Mater. Interfaces. 2016;8:25051&#x2013;25059. doi: 10.1021/acsami.6b06446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.6b06446</ArticleId><ArticleId IdType="pubmed">27598554</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos T., Boto C., Saraiva C.M., Bernardino L., Ferreira L. Nanomedicine approaches to modulate neural stem cells in brain repair. Trends Biotechnol. 2016;34:437&#x2013;439. doi: 10.1016/j.tibtech.2016.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2016.02.003</ArticleId><ArticleId IdType="pubmed">26917252</ArticleId></ArticleIdList></Reference><Reference><Citation>Entekhabi E., Haghbin Nazarpak M., Moztarzadeh F., Sadeghi A. Design and manufacture of neural tissue engineering scaffolds using hyaluronic acid and polycaprolactone nanofibers with controlled porosity. Mater. Sci. Eng. C Mater. Biol. Appl. 2016;69:380&#x2013;387. doi: 10.1016/j.msec.2016.06.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msec.2016.06.078</ArticleId><ArticleId IdType="pubmed">27612726</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae H., Chu H., Edalat F., Cha J.M., Sant S., Kashyap A., Ahari A.F., Kwon C.H., Nichol J.W., Manoucheri S., et al. Development of functional biomaterials with micro- and nanoscale technologies for tissue engineering and drug delivery applications. J. Tissue Eng. Regen. Med. 2014;8:1&#x2013;14. doi: 10.1002/term.1494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/term.1494</ArticleId><ArticleId IdType="pmc">PMC4199309</ArticleId><ArticleId IdType="pubmed">22711442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuihua Z., Chunyang W., Cunyi F., Xiumei M. Aligned SF/P(LLA-CL)-blended nanofibers encapsulating nerve growth factor for peripheral nerve regeneration. J. Biomed. Mater. Res. A. 2014;102:2680&#x2013;2691. doi: 10.1002/jbm.a.34922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.34922</ArticleId><ArticleId IdType="pubmed">23963979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan J., Noakes P.G., Bellingham M.C. The role of altered BDNF/TrkB signaling in Amyotrophic Lateral Sclerosis. Front. Cell Neurosci. 2019;13:368. doi: 10.3389/fncel.2019.00368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00368</ArticleId><ArticleId IdType="pmc">PMC6700252</ArticleId><ArticleId IdType="pubmed">31456666</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakotoarisoa M., Angelov B., Drechsler M., Nicolas V., Bizien T., Gorshkova Y.E., Deng Y., Angelova A. Liquid crystalline lipid nanoparticles for combined delivery of curcumin, fish oil and BDNF: In vitro neuroprotective potential in a cellular model of tunicamycin-induced endoplasmic reticulum stress. Smart Mater. Med. 2022;3:274&#x2013;288. doi: 10.1016/j.smaim.2022.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smaim.2022.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Nagappan G., Lu B. Differential effects of transient and sustained activation of BDNF-TrkB signaling. Dev. Neurobiol. 2018;78:647&#x2013;659. doi: 10.1002/dneu.22592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.22592</ArticleId><ArticleId IdType="pubmed">29575722</ArticleId></ArticleIdList></Reference><Reference><Citation>Minuzzi L.G., Seelaender M., Silva B.S.D.A., Cunha E.d.B.B., Deus M.D.C., Vasconcellos F.T.F., Marqueze L.F.B., Gadotti A.C., Baena C.P., Pereira T., et al. COVID-19 outcome relates with circulating BDNF, according to patient adiposity and age. Front. Nutr. 2021;8:784429. doi: 10.3389/fnut.2021.784429.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2021.784429</ArticleId><ArticleId IdType="pmc">PMC8704131</ArticleId><ArticleId IdType="pubmed">34957187</ArticleId></ArticleIdList></Reference><Reference><Citation>Motaghinejad M., Gholami M. Possible neurological and mental outcomes of COVID-19 infection: A hypothetical role of ACE-2\Mas\BDNF signaling pathway. Int. J. Prev. Med. 2020;11:84. doi: 10.4103/ijpvm.IJPVM_114_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijpvm.IJPVM_114_20</ArticleId><ArticleId IdType="pmc">PMC7518341</ArticleId><ArticleId IdType="pubmed">33042481</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa C., Rivellini E., Lavitrano M., Combi R. Can SARS-CoV-2 Infection exacerbate Alzheimer&#x2019;s disease? An overview of shared risk factors and pathogenetic mechanisms. J. Pers. Med. 2021;12:29. doi: 10.3390/jpm12010029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12010029</ArticleId><ArticleId IdType="pmc">PMC8780286</ArticleId><ArticleId IdType="pubmed">35055344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng T.K.S., Ho C.S.H., Tam W.W.S., Kua E.H., Ho R.C.M. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer&#x2019;s disease (AD): A systematic review and meta-analysis. Int. J. Mol. Sci. 2019;20:257. doi: 10.3390/ijms20020257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020257</ArticleId><ArticleId IdType="pmc">PMC6358753</ArticleId><ArticleId IdType="pubmed">30634650</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris N.M., Ritzel R., Mancini N.S., Jiang Y., Yi X., Manickam D.S., Banks W.A., Kabanov A.V., McCullough L.D., Verma R. Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery. Pharmacol. Biochem. Behav. 2016;150&#x2013;151:48&#x2013;56. doi: 10.1016/j.pbb.2016.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2016.09.003</ArticleId><ArticleId IdType="pmc">PMC5145740</ArticleId><ArticleId IdType="pubmed">27619636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Fay J.M., Poon C.D., Vinod N., Zhao Y., Bullock K., Qin S., Manickam D.S., Yi X., Banks W.A., et al. Nanoformulation of brain-derived neurotrophic factor with target receptor-triggered-release in the central nervous system. Adv. Funct. Mater. 2018;28:1703982. doi: 10.1002/adfm.201703982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201703982</ArticleId><ArticleId IdType="pmc">PMC5958903</ArticleId><ArticleId IdType="pubmed">29785179</ArticleId></ArticleIdList></Reference><Reference><Citation>Limongi T., Rocchi A., Cesca F., Tan H., Miele E., Giugni A., Orlando M., Perrone Donnorso M., Perozziello G., Benfenati F., et al. Delivery of brain-derived neurotrophic factor by 3D biocompatible polymeric scaffolds for neural tissue engineering and neuronal regeneration. Mol. Neurobiol. 2018;55:8788&#x2013;8798. doi: 10.1007/s12035-018-1022-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1022-z</ArticleId><ArticleId IdType="pubmed">29600349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassannejad Z., Zadegan S.A., Vaccaro A.R., Rahimi-Movaghar V., Sabzevari O. Biofunctionalized peptide-based hydrogel as an injectable scaffold for BDNF delivery can improve regeneration after spinal cord injury. Injury. 2019;50:278&#x2013;285. doi: 10.1016/j.injury.2018.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.12.027</ArticleId><ArticleId IdType="pubmed">30595411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D.J., Nguyen C., Chun H.N.L., Llorente I., Chiu A.S., Machnicki M., Zarembinski T.I., Carmichael S.T. Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke. J. Cereb. Blood Flow. Metab. 2017;37:1030&#x2013;1045. doi: 10.1177/0271678X16649964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X16649964</ArticleId><ArticleId IdType="pmc">PMC5363479</ArticleId><ArticleId IdType="pubmed">27174996</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeyer J.M., Tuladhar A., Payne S.L., Ho E., Morshead C.M., Shoichet M.S. Local delivery of brain-derived neurotrophic factor enables behavioral recovery and tissue repair in stroke-injured rats. Tissue Eng. Part A. 2019;25:1175&#x2013;1187. doi: 10.1089/ten.tea.2018.0215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ten.tea.2018.0215</ArticleId><ArticleId IdType="pubmed">30612516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandalam S., Sindji L., Delcroix G.J., Violet F., Garric X., Andr&#xe9; E.M., Schiller P.C., Venier-Julienne M.C., des Rieux A., Guicheux J., et al. Pharmacologically active microcarriers delivering BDNF within a hydrogel: Novel strategy for human bone marrow-derived stem cells neural/neuronal differentiation guidance and therapeutic secretome enhancement. Acta Biomater. 2017;49:167&#x2013;180. doi: 10.1016/j.actbio.2016.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2016.11.030</ArticleId><ArticleId IdType="pubmed">27865962</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y., Wen C.Y., Li S.T., Xia Z.X. Non-viral liposome-mediated transfer of brain-derived neurotrophic factor across the blood-brain barrier. Neural Regen. Res. 2016;11:617&#x2013;622. doi: 10.4103/1673-5374.180747.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.180747</ArticleId><ArticleId IdType="pmc">PMC4870919</ArticleId><ArticleId IdType="pubmed">27212923</ArticleId></ArticleIdList></Reference><Reference><Citation>Low W.C., Rujitanaroj P.O., Wang F., Wang J., Chew S.Y. Nanofiber-mediated release of retinoic acid and brain-derived neurotrophic factor for enhanced neuronal differentiation of neural progenitor cells. Drug Deliv. Transl. Res. 2015;5:89&#x2013;100. doi: 10.1007/s13346-013-0131-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-013-0131-5</ArticleId><ArticleId IdType="pubmed">25787735</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N., Schulze J., Warwas D.P., Ehlert N., Lenarz T., Warnecke A., Behrens P. Long-term delivery of brain-derived neurotrophic factor (BDNF) from nanoporous silica nanoparticles improves the survival of spiral ganglion neurons in vitro. PLoS ONE. 2018;13:e0194778. doi: 10.1371/journal.pone.0194778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0194778</ArticleId><ArticleId IdType="pmc">PMC5870973</ArticleId><ArticleId IdType="pubmed">29584754</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Chau Y. Polymeric nanoparticles decorated with BDNF-derived peptide for neuron-targeted delivery of PTEN inhibitor. Eur. J. Pharm. Sci. 2018;124:37&#x2013;45. doi: 10.1016/j.ejps.2018.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2018.08.020</ArticleId><ArticleId IdType="pubmed">30145338</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x105;bkowska M., &#x141;uczkowska K., Rogi&#x144;ska D., Sobu&#x15b; A., Wasilewska M., Ula&#x144;czyk Z., Machali&#x144;ski B. Novel design of (PEG-ylated)PAMAM-based nanoparticles for sustained delivery of BDNF to neurotoxin-injured differentiated neuroblastoma cells. J. Nanobiotechnol. 2020;18:120. doi: 10.1186/s12951-020-00673-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-020-00673-8</ArticleId><ArticleId IdType="pmc">PMC7457365</ArticleId><ArticleId IdType="pubmed">32867843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Yan X., Sun X., Shen X., Yin H., Wang C., Liu Y., Lu C., Fu H., Yang S., et al. Synergistic effects of dual-presenting VEGF- and BDNF-mimetic peptide epitopes from self-assembling peptide hydrogels on peripheral nerve regeneration. Nanoscale. 2019;11:19943&#x2013;19958. doi: 10.1039/C9NR04521J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C9NR04521J</ArticleId><ArticleId IdType="pubmed">31602446</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelbrock A.N., &#xc0;lvarez Z., Simkin D., Fyrner T., Chin S.M., Sato K., Kiskinis E., Stupp S.I. Supramolecular nanostructure activates TrkB receptor signaling of neuronal cells by mimicking brain-derived neurotrophic factor. Nano Lett. 2018;18:6237&#x2013;6247. doi: 10.1021/acs.nanolett.8b02317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.8b02317</ArticleId><ArticleId IdType="pmc">PMC6207372</ArticleId><ArticleId IdType="pubmed">30211565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes C.D.F., Gon&#xe7;alves N.P., Gomes C.P., Saraiva M.J., P&#xea;go A.P. BDNF gene delivery mediated by neuron-targeted nanoparticles is neuroprotective in peripheral nerve injury. Biomaterials. 2017;121:83&#x2013;96. doi: 10.1016/j.biomaterials.2016.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2016.12.025</ArticleId><ArticleId IdType="pubmed">28081461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Yuan J., Chen X., Xu J., Li Y., Dong P. Functional regeneration of the transected recurrent laryngeal nerve using a collagen scaffold loaded with laminin and laminin-binding BDNF and GDNF. Sci. Rep. 2016;6:32292. doi: 10.1038/srep32292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep32292</ArticleId><ArticleId IdType="pmc">PMC4997630</ArticleId><ArticleId IdType="pubmed">27558932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravina K., Briggs D.I., Kislal S., Warraich Z., Nguyen T., Lam R.K., Zarembinski T.I., Shamloo M. Intracerebral delivery of brain-derived neurotrophic factor using HyStem&#xae;-C hydrogel implants improves functional recovery and reduces neuroinflammation in a rat model of ischemic stroke. Int. J. Mol. Sci. 2018;19:3782. doi: 10.3390/ijms19123782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19123782</ArticleId><ArticleId IdType="pmc">PMC6321015</ArticleId><ArticleId IdType="pubmed">30486515</ArticleId></ArticleIdList></Reference><Reference><Citation>Gransee H.M., Zhan W.Z., Sieck G.C., Mantilla C.B. Localized delivery of brain-derived neurotrophic factor-expressing mesenchymal stem cells enhances functional recovery following cervical spinal cord injury. J. Neurotrauma. 2015;32:185&#x2013;193. doi: 10.1089/neu.2014.3464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3464</ArticleId><ArticleId IdType="pmc">PMC4298751</ArticleId><ArticleId IdType="pubmed">25093762</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Sandner B., Schackel T., Nicholson L., Chtarto A., Tenenbaum L., Puttagunta R., M&#xfc;ller R., Weidner N., Blesch A. Regulated viral BDNF delivery in combination with Schwann cells promotes axonal regeneration through capillary alginate hydrogels after spinal cord injury. Acta Biomater. 2017;60:167&#x2013;180. doi: 10.1016/j.actbio.2017.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2017.07.024</ArticleId><ArticleId IdType="pubmed">28735026</ArticleId></ArticleIdList></Reference><Reference><Citation>Schendzielorz P., Scherzed A., Rak K., V&#xf6;lker J., Hagen R., Mlynski R., Fr&#xf6;lich K., Radeloff A. A hydrogel coating for cochlear implant arrays with encapsulated adipose-derived stem cells allows brain-derived neurotrophic factor delivery. Acta Otolaryngol. 2014;134:497&#x2013;505. doi: 10.3109/00016489.2013.878809.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00016489.2013.878809</ArticleId><ArticleId IdType="pubmed">24646140</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova A., Drechsler M., Garamus V.M., Angelov B. Liquid crystalline nanostructures as PEGylated reservoirs of omega-3 polyunsaturated fatty acids: Structural insights toward delivery formulations against neurodegenerative disorders. ACS Omega. 2018;3:3235&#x2013;3247. doi: 10.1021/acsomega.7b01935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.7b01935</ArticleId><ArticleId IdType="pmc">PMC6044969</ArticleId><ArticleId IdType="pubmed">30023865</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerzoni L.P.B., Nicolas V., Angelova A. In vitro modulation of TrkB receptor signaling upon sequential delivery of curcumin-DHA loaded carriers towards promoting neuronal survival. Pharm. Res. 2017;34:492&#x2013;505. doi: 10.1007/s11095-016-2080-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-016-2080-4</ArticleId><ArticleId IdType="pubmed">27995523</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujino T., Yamada T., Asada T., Tsuboi Y., Wakana C., Mawatari S., Kono S. Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer&#x2019;s disease and mild cognitive impairment: A multicenter, randomized, double-blind, placebo-controlled trial. eBiomedicine. 2017;17:199&#x2013;205. doi: 10.1016/j.ebiom.2017.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2017.02.012</ArticleId><ArticleId IdType="pmc">PMC5360580</ArticleId><ArticleId IdType="pubmed">28259590</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Angelova A. Coronavirus-induced host cubic membranes and lipid-related antiviral therapies: A focus on bioactive plasmalogens. Front. Cell Dev. Biol. 2021;9:630242. doi: 10.3389/fcell.2021.630242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.630242</ArticleId><ArticleId IdType="pmc">PMC8006408</ArticleId><ArticleId IdType="pubmed">33791293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain M.S., Mawatari S., Fujino T. Plasmalogens, the vinyl ether-linked glycerophospholipids, enhance learning and memory by regulating brain-derived neurotrophic factor. Front. Cell Dev. Biol. 2022;10:828282. doi: 10.3389/fcell.2022.828282.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.828282</ArticleId><ArticleId IdType="pmc">PMC8864319</ArticleId><ArticleId IdType="pubmed">35223852</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova A., Angelov B., Drechsler M., Bizien T., Gorshkova Y.E., Deng Y. Plasmalogen-based liquid crystalline multiphase structures involving docosapentaenoyl derivatives inspired by biological cubic membranes. Front. Cell Dev. Biol. 2021;9:617984. doi: 10.3389/fcell.2021.617984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.617984</ArticleId><ArticleId IdType="pmc">PMC7905036</ArticleId><ArticleId IdType="pubmed">33644054</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H., Oh J., Shim G., Cho B., Chang Y., Kim S., Baek S., Kim H., Shin J., Cho H., et al. In vivo neuronal gene editing via CRISPR&#x2013;Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer&#x2019;s disease. Nat Neurosci. 2019;22:524&#x2013;528. doi: 10.1038/s41593-019-0352-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0352-0</ArticleId><ArticleId IdType="pubmed">30858603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolli N., Lu M., Maiti P., Rossignol J., Dunbar G.L. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases. Neurochem. Int. 2018;112:187&#x2013;196. doi: 10.1016/j.neuint.2017.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2017.07.007</ArticleId><ArticleId IdType="pubmed">28732771</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan L., Han Y., Yang C., Lu S., Du J., Li H., Lin J. CRISPR-Cas9-mediated gene therapy in neurological disorders. Mol. Neurobiol. 2022;59:968&#x2013;982. doi: 10.1007/s12035-021-02638-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02638-w</ArticleId><ArticleId IdType="pubmed">34813019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozhin A., Batasheva S., Kruychkova M., Cherednichenko Y., Rozhina E., Fakhrullin R. Biogenic silver nanoparticles: Synthesis and application as antibacterial and antifungal Agents. Micromachines. 2021;12:1480. doi: 10.3390/mi12121480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mi12121480</ArticleId><ArticleId IdType="pmc">PMC8708042</ArticleId><ArticleId IdType="pubmed">34945330</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>